Inc., located in Vicksburg, Mississippi (Subzone 158E), at the locations described in the application, subject to the FTZ Act and the Board's regulations, including § 400.28, and subject to the following conditions:

1. Foreign status (19 CFR 146.41, 146.42) products consumed as fuel for the petrochemical complex shall be subject to the applicable duty rate.

- 2. Privileged foreign status (19 CFR 146.41) shall be elected on all foreign merchandise admitted to the subzone, except that non-privileged foreign (NPF) status (19 CFR 146.42) may be elected on refinery inputs covered under HTSUS Subheadings #2709.00.10, #2709.00.20, #2710.11.25, #2710.11.45, #2710.19.05, #2710.19.07, #2710.99.10, #2710.99.16, #2710.99.21 and #2710.99.45 which are used in the production of:
- —Petrochemical feedstocks (examiners report, Appendix "C");

—Products for export;

—And, products eligible for entry under HTSUS # 9808.00.30 and # 9808.00.40 (U.S. Government purchases).

Signed at Washington, DC, this 25th day of August 2003.

Jeffrey May,

Acting Assistant Secretary of Commerce for Import Administration, Alternate Chairman, Foreign-Trade Zones Board.

[FR Doc. 03–23066 Filed 9–9–03; 8:45 am] **BILLING CODE 3510–DS–P**

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Order No. 1296]

Approval for Expansion of Subzone 61F IPR Pharmaceuticals, Inc., Plant (Pharmaceuticals) Guayama, PR

Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a–81u), the Foreign-Trade Zones Board (the Board) adopts the following Order:

Whereas, the Puerto Rico Exports Development Corporation, grantee of FTZ 61, has requested authority on behalf of IPR Pharmaceuticals, Inc., to expand the subzone boundaries and to expand the scope of manufacturing authority under zone procedures in terms of both products and capacity at Subzone 61F at the IPR Pharmaceutical, Inc., plant in Guayama, Puerto Rico (FTZ Docket 30–2002, filed 8/1/2002);

Whereas, notice inviting public comment has been given in the **Federal Register** (67 FR 51820, 8/09/02);

Whereas, the Board adopts the findings and recommendation of the examiner's report, and finds that the requirements of the FTZ Act and Board's regulations are satisfied, and that the proposal is in the public interest;

Now, therefore, the Board hereby orders: The application to add capacity and to expand the scope of authority under zone procedures within Subzone 61F on behalf of IPR Pharmaceuticals, Inc., is approved, subject to the FTZ Act and the Board's regulations, including Section 400.28.

Signed at Washington, DC, this 25th day of August 2003.

Jeffrey May,

Acting Assistant Secretary of Commerce for Import Administration, Alternate Chairman, Foreign-Trade Zones Board.

Dennis Puccinelli,

Executive Secretary.

[FR Doc. 03–23065 Filed 9–9–03; 8:45 am] BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Order No. 1292]

Approval for Extension of Authority of Board Order 875; Baxter Healthcare Corporation (Pharmaceutical Products), Guayama, PR

Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a-81u), the Foreign-Trade Zones Board (the Board) adopts the following Order:

Whereas, Board Order 875 (62 FR 10521, 3/7/97) approved the request of the Puerto Rico Exports Development Corporation, grantee of Foreign-Trade Zone 61, for pharmaceutical manufacturing authority at the Baxter Healthcare Corporation (Baxter) facility in Guayama, Puerto Rico (Subzone 61H);

Whereas, the authority was approved at the outset for five years, subject to extension:

Whereas, the Puerto Rico Exports Development Corporation, grantee of Foreign-Trade Zone 61, has requested authority, on behalf of Baxter, to extend its manufacturing authority on a permanent basis (FTZ Doc. 11–2002, filed 2/7/2002);

Whereas, notice inviting public comment has been given in the **Federal Register** (67 FR 7132, 2/15/2002);

Whereas, the Board adopts the findings and recommendations of the examiner's report, and finds that the requirements of the FTZ Act and the

Board's regulations are satisfied, and that approval of the request is in the public interest;

Now, Therefore, the Board hereby approves the request subject to the FTZ Act and the Board's regulations, including section 400.28.

Signed at Washington, DC, this 25th day of August, 2003.

Jeffrey May,

Acting Assistant Secretary of Commerce for Import Administration, Alternate Chairman, Foreign-Trade Zones Board.

[FR Doc. 03–23070 Filed 9–9–03; 8:45 am] BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Order No. 1293]

Approval for Expansion of Facilities and Manufacturing Authority at Subzone 61H; Baxter Healthcare Corporation Plant (Pharmaceuticals), Guayama, PR

Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a–81u), the Foreign-Trade Zones Board (the Board) adopts the following Order:

Whereas, the Puerto Rico Exports Development Corporation, grantee of Foreign-Trade Zone 61, has requested authority on behalf of Baxter Healthcare Corporation (Baxter), to expand the subzone boundaries and to expand the scope of manufacturing authority in terms of products and capacity under zone procedures within Subzone 61H at the Baxter pharmaceutical manufacturing plant in Guayama, Puerto Rico (FTZ Docket 35–2002, filed 9/10/2002);

Whereas, notice inviting public comment has been given in the **Federal Register** (67 FR 58584, 9/17/02);

Whereas, the Board adopts the findings and recommendations of the examiner's report, and finds that the requirements of the FTZ Act and Board's regulations are satisfied, and that the proposal is in the public interest;

Now, therefore, the Board hereby orders:

The application to add capacity and to expand the scope of manufacturing authority under zone procedures within Subzone 61H at the pharmaceutical manufacturing plant of Baxter Healthcare Corporation in Guayama, Puerto Rico, is approved, subject to the FTZ Act and the Board's regulations, including Section 400.28.